Visgenx is developing therapeutics to protect against the loss of sight from retinal disorders. Our programs are based on modulating a novel gene target which may underlie the loss of retinal cells critical to vision.
Age Related Macular Degeneration / Geographic Atrophy
Our fast to market approach is based on increasing expression of the target gene by repurposing the de-methylating agent decitabine. Our longer term goal is gene therapy or an mRNA based therapeutic.